BioMimetic Therapeutics (BMTI)
BioMimetic Therapeutics Key Statistics
Pro Data ExportCurrent Valuation
Dividends and Shares
| Dividend | |
| Dividend Yield | 0.00% |
| Cash Div. Payout Ratio TTM Pro | Go Pro |
| Payout Ratio TTM Pro | Go Pro |
| Dividend Date | |
| Ex-Dividend Date | |
| Last Split Factor | |
| Last Split Date |
Profitability
| Gross Profit Margin | 96.68% |
| EBITDA Margin TTM Pro | Go Pro |
| Operating Margin TTM Pro | Go Pro |
| Profit Margin | -1312% |
Management Effectiveness
Liquidity and Solvency
| Altman Z-Score Pro | Go Pro |
| Current Ratio | 14.66 |
| Debt to Equity Ratio | 0.0023 |
| KZ Index Pro | Go Pro |
| Tangible Common Equity Ratio Pro | Go Pro |
| Times Interest Earned TTM Pro | Go Pro |
Stock Price Performance
| Beta Pro | Go Pro |
| 1 Month Stock Returns | -9.67% |
| Year to Date Stock Returns | -14.74% |
| 1 Year Stock Returns | -70.00% |
| 3 Year Stock Returns | -70.29% |
| 52 Week High | 8.35 |
| 52 Week Low | 1.87 |
Income Statement
| Revenues TTM | 1.793M |
| Revenue Per Share TTM | 0.0637 |
| Revenue Growth | 16.98% |
| Gross Profit TTM | 1.736M |
| EBITDA TTM Pro | Go Pro |
| Income from Cont. Ops Pro | Go Pro |
| Net Income TTM | -31.35M |
| Earnings Per Share TTM | -1.13 |
| Other Comprehensive Income Pro | Go Pro |
Cash Flow Statement
| Cash Investing TTM | 22.93M |
| Cash Financing TTM | 0.2073M |
| Cash Operations TTM | -27.66M |
| Capital Expenditures | 0.0093M |
Share Statistics
| Shares Outstanding | 28.13M |
Balance Sheet
| Cash and ST Investments | 54.51M |
| Total Assets | 66.94M |
| Liabilities | 18.13M |
| Book Value | 48.81M |
| Book Value per Share | 1.735 |
| Tangible Book Value Pro | Go Pro |
| Tangible Book Value Per Share Pro | Go Pro |
| Long Term Debt | 0.1105M |
Earnings Quality
| Accruals Pro | Go Pro |
| Beneish M-Score Pro | Go Pro |
You may also be interested in these BMTI related companies
BMTI News
Listen to $BMTI Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3kfu
about 18 days ago by earningscast
about 18 days ago by earningscast
BioMimetic Therapeutics, Inc. Reports First Quarter 2012 Earnings Results
May 09, 4:00PM Business Wire
May 09, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Report First Quarter 2012 Financial Results on May 9
May 07, 11:00AM Business Wire
May 07, 11:00AM Business Wire
BioMimetic (BMTI) Shares Rallying on Very Heavy Volume, Stock Now Up Nearly 7%
Apr 04, 1:53PM Street Insider
Apr 04, 1:53PM Street Insider
@ACInvestorBlog $BMTI - what developments do you see that might move this stock up or down? And forget about insider purchases.
about 54 days ago by gregthor
about 54 days ago by gregthor
Listen to $BMTI Q4 2011 earnings call - live at 04:30 PM, ondemand after - http://stks.co/2pPl
about 75 days ago by earningscast
about 75 days ago by earningscast
BioMimetic Therapeutics, Inc. (BMTI) Posts Wider than Expected Q4 Loss
Mar 13, 4:00PM Street Insider
Mar 13, 4:00PM Street Insider
BioMimetic Therapeutics, Inc. Reports Fourth Quarter and Year-End 2011 Earnings Results
Mar 13, 4:00PM Business Wire
Mar 13, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Report 2011 Fourth Quarter and Year-End Financial Results on March 13
Mar 09, 2:27PM Business Wire
Mar 09, 2:27PM Business Wire
$BMTI http://stks.co/2kdZ Look For A Move Over The Range Break And Then 50 EMA At 2.24.
about 80 days ago by XiATH
about 80 days ago by XiATH
BioMimetic Therapeutics, Inc. to Introduce Augmatrix™ Biocomposite Bone Graft Product Line at AAOS
Feb 08, 9:25AM Business Wire
Feb 08, 9:25AM Business Wire
$BMTI too risky. Strong Buys $SINO,target $6 $ONTY $OCZ lots of room to run
about 110 days ago by contrarian1
about 110 days ago by contrarian1
Collins Stewart Reiterates a 'Buy' on BioMimetic Therapeutics (BMTI); Positive Pilot Study Offer Another Sizable Opportunity
Feb 07, 11:05AM Street Insider
Feb 07, 11:05AM Street Insider
BioMimetic Therapeutics, Inc. to Highlight Product Development Activities at ORS and AAOS Meetings
Feb 06, 4:00PM Business Wire
Feb 06, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 10, 11:00AM Business Wire
Jan 10, 11:00AM Business Wire
Wedbush Downgrades BioMimetic Therapeutics (BMTI) to Neutral, Still See Approval of Augment Bone Graft
Jan 04, 12:18PM Street Insider
Jan 04, 12:18PM Street Insider
$BMTI BioMimetic Therapeutics downgraded to Neutral from Outperform at Wedbush
about 144 days ago by _TheBlackSwan_
about 144 days ago by _TheBlackSwan_
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMTI | 2.43 | +0.02 | +0.83% | 68.36M |
| BMRN | 38.64 | +0.13 | +0.34% | 4.468B |
| BMJ | 0.93 | +0.00 | +0.00% | |
| BMI | 36.69 | -0.25 | -0.68% | 550.35M |
| BMC | 43.69 | +0.72 | +1.68% | 7.175B |
| BMA | 13.46 | -0.33 | -2.39% | 785.12M |
| BLX | 19.14 | -0.08 | -0.42% | 540.90M |
| BLV | 93.83 | +0.41 | +0.44% | |
| BLTI | 2.42 | +0.06 | +2.54% | 74.27M |
| BLT | 13.53 | -0.11 | -0.81% | 662.16M |
